NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasisNICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but Share XNICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasishttps://pharmaphorum.com/news/nice-okays-ucbs-cimzia-nixes-almirall-ilumetri-in-psoriasis/
New UK drug pricing deal promises faster medicines accessThe UK government has reached a new five-year medicines pricing deal with the pharma industry to replace the Share XNew UK drug pricing deal promises faster medicines accesshttps://pharmaphorum.com/news/new-uk-drug-pricing-deal-promises-faster-medicines-access/
Vertex wins European approval for new cystic fibrosis combinationEuropean regulators have approved Vertex’s new cystic fibrosis (CF) combination treatment Symkevi. The European Commission’s greenlight for Symkevi Share XVertex wins European approval for new cystic fibrosis combinationhttps://pharmaphorum.com/news/vertex-european-approval-cystic-fibrosis/
How the NHS got ahead of the curve with CAR-TThe UK’s pharma industry has welcomed the NHS’ fast adoption of the latest CAR-T cancer therapies. Richard Staines Share XHow the NHS got ahead of the curve with CAR-Thttps://pharmaphorum.com/views-analysis-oncology/nhs-got-ahead-curve-car-t/
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICENICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not a cost-effective Share XAbbVie’s CLL drug Venclyxto too expensive for NHS, says NICEhttps://pharmaphorum.com/news/abbvies-cll-drug-venclyxto-too-expensive-for-nhs-says-nice/
Can managed access agreements help unlock access through the NICE Highly Specialised Technology Appraisal Process?The National Institute for Health and Care Excellence (NICE) process for single technology appraisals (STA) has been established Share XCan managed access agreements help unlock access through the NICE Highly Specialised Technology Appraisal Process?https://pharmaphorum.com/market-access-2/can-managed-access-agreements-help-unlock-access-through-the-nice-highly-specialised-technology-appraisal-process/
Novartis challenges court ruling allowing use of Avastin in wet AMDNovartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Share XNovartis challenges court ruling allowing use of Avastin in wet AMDhttps://pharmaphorum.com/news/novartis-challenges-court-ruling-allowing-use-of-avastin-in-wet-amd/
Collaboration can ensure access to life-changing innovationAs a pioneering risk sharing scheme has shown, new medications can be the catalyst for a whole new Share XCollaboration can ensure access to life-changing innovationhttps://pharmaphorum.com/views-analysis-market-access/access-life-changing-innovation-risk-sharing-scheme/
CSL Behring lung drug would cost NHS £8m per patient, says NICENICE has rejected CSL Behring’s alpha1-proteinase inhibitor Respreeza for treating genetic emphysema in draft guidance, saying that it Share XCSL Behring lung drug would cost NHS £8m per patient, says NICEhttps://pharmaphorum.com/news/csl-behring-lung-drug-would-cost-nhs-8m-per-patient-says-nice/
